Boston Scientific Corp.

While Boston Scientific reported revenue growth of approximately 5 percent in the fourth quarter of 2015, that ended up being approximately $16 million below what was expected and the company's stock took a hit.

Boston Scientific has partnered with Accenture to create a cloud-based analytics program that allows caregivers to crunch the numbers in an effort to improve treatment for patients with chronic cardiovascular diseases.

Framingham-based Boston Scientific Corp. has launched a new, single-used ureteroscope designed to eliminate maintenance while still diagnosing stones and other kidney and bladder conditions.

Marlborough-based Boston Scientific has issued a global recall on its Chariot Guiding Sheath following 14 complaints of failure, including while the device was inside patients, which could lead to obstruction of blood flow causing stroke or kidney damage.

Five companies located in the MetroWest region earned the highest scores possible on the Human Rights Campaign's annual Corporate Equality Index (CEI), that measures major companies' lesbian, gay, bisexual and transgender (LGBT) inclusion in the workplace.

Marlborough-based Boston Scientific will expand its cancer treatment portfolio with the $70 million purchase of a portion of Texas-based CeloNova Biosciences.

Despite a third-quarter net loss of $198 million, profits at Marlborough-based Boston Scientific edged above most analysts’...

Marlborough-based Boston Scientific Wednesday announced it is providing a new round of financing for MValve Technologies, which operates in Herzliya, Israel and San Diego.

A drug-delivering and self-dissolving arterial stent made by Boston Scientific has received Food and Drug Administration approval, the Marlborough-based company announced.

Boston Scientific of Marlborough has received Food and Drug Administration approval for its Innova stent system for treatment of patients with peripheral artery disease.